Company Profile

Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinsonâ€™s disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Employees

102

Sector

Biotechnology & Medical Research

More about the company

13/08/24	First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.	CI
07/08/24	Modified First Amended Joint Liquidation Plan Approved for Acorda Therapeutics, Inc.	CI
30/07/24	First Motion for Exclusivity Period Extension Filed by Acorda Therapeutics, Inc.	CI
10/07/24	Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.	CI
03/07/24	Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.	CI
01/07/24	First Amended Joint Liquidation Plan and Disclosure Statement Filed by Acorda Therapeutics, Inc.	CI
12/06/24	Motion for Asset Sale Approved for Acorda Therapeutics, Inc.	CI
14/05/24	Acorda Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/05/24	Liquidation Plan and Disclosure Statement Filed by Acorda Therapeutics, Inc.	CI
03/05/24	Final DIP Financing Approved for Acorda Therapeutics, Inc.	CI
29/04/24	Bidding Procedure Approved for Acorda Therapeutics, Inc.	CI
16/04/24	Acorda Therapeutics Delisted from Nasdaq, Now Trading on OTC Pink Market	MT
05/04/24	Interim DIP Financing Approved for Acorda Therapeutics, Inc.	CI

07/08/25	Federal Circuit Denies Appellate Jurisdiction Based On Alternative Ground For Relief	AQ
09/08/24	Acorda Therapeutics : UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK Form 8 K	PU
12/07/24	Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics	AQ
14/05/24	Acorda: Q1 Earnings Snapshot	AQ
16/04/24	Acorda Therapeutics Announces Delisting from Nasdaq	BU

Date	Insider	Type	Main position	Quantity	% Market Cap.
22/6/23	John Kelley	Free	Chairman	1,200	0.0049%
22/6/23	Thomas Burns	Free	Director	2,400	0.0099%
22/6/23	Peder Jensen	Free	Director	1,200	0.0049%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACORDA THERAPEUTICS, INC.	-3.57%	-38.64%	-	-	16.77K
WUXI APPTEC CO., LTD.	-2.11%	-1.68%	+44.52%	+95.15%	66.93B
ARGENX SE	-0.23%	-4.45%	+30.39%	+73.64%	61.97B
INSMED INCORPORATED	+1.67%	+2.47%	-11.23%	+388.34%	28.27B
WUXI BIOLOGICS (CAYMAN) INC.	-1.05%	-4.43%	+30.56%	+10.07%	24.59B
BIONTECH SE	+0.34%	-6.78%	-7.27%	-17.99%	24.3B
GENMAB A/S	+0.43%	-3.37%	+14.85%	-19.29%	19.41B
PHARMAESSENTIA CORPORATION	-3.03%	-2.29%	+185.12%	+334.07%	16.77B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.94%	-4.94%	-5.29%	+495.65%	14.18B
EXELIXIS, INC.	-2.28%	-4.90%	+43.64%	+155.21%	13.91B
Average	-1.18%	-3.46%	+36.14%	+168.32%	30.04B
Weighted average by Cap.	-0.84%	-3.06%	+33.46%	+133.67%

Acorda Therapeutics, Inc. Stock

Stocks

ACOR.Q

US00484M7002

Biotechnology & Medical Research

Latest news : Acorda Therapeutics, Inc.

Press Releases : Acorda Therapeutics, Inc.

Quotes and Performance

Managers and Directors : Acorda Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile